Literature DB >> 30588315

Catheter Ablation for Atrial Fibrillation in Systolic Heart Failure Patients: Stone by Stone, a CASTLE.

Dimitrios Vrachatis1, Spyridon Deftereos2,3, Vasileios Kekeris1, Styliani Tsoukala1, Georgios Giannopoulos1,2.   

Abstract

Heart failure (HF) and AF frequently coexist and are involved in a vicious cycle of adverse pathophysiologic interactions. Applying treatment algorithms that have been validated in the general AF population to patients with AF and HF may be fraught with risks and lack effectiveness. While firm recommendations on using catheter ablation for AF do exist, the subset of patients also suffering from HF needs to be further evaluated. Observational data indicate that a significant number of ablation procedures are performed in patients with coexistent HF. Initial randomised data on outcomes are encouraging. Apart from sinus rhythm maintenance, benefits have been observed in terms of other significant endpoints, including left ventricular ejection fraction, quality of life, exercise capacity and hospital readmissions for HF. Limited existing data on survival are also promising. In the present article, observational and randomised studies along with current practice guidelines are summarised.

Entities:  

Keywords:  Pulmonary vein isolation; atrial fibrillation; catheter ablation; cryoablation; cryoballoon; radiofrequency; systolic heart failure

Year:  2018        PMID: 30588315      PMCID: PMC6304798          DOI: 10.15420/aer.2018.41.2

Source DB:  PubMed          Journal:  Arrhythm Electrophysiol Rev        ISSN: 2050-3369


  1 in total

1.  Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation.

Authors:  Marc Girod; Michael Coslovsky; Stefanie Aeschbacher; Christian Sticherling; Tobias Reichlin; Laurent Roten; Nicolas Rodondi; Peter Ammann; Angelo Auricchio; Giorgio Moschovitis; Richard Kobza; Patrick Badertscher; Sven Knecht; Philipp Krisai; Andrea Marugg; Helena Aebersold; Elisa Hennings; Miquel Serra-Burriel; Matthias Schwenkglenks; Christine S Zuern; Leo H Bonati; David Conen; Stefan Osswald; Michael Kühne
Journal:  Clin Res Cardiol       Date:  2022-04-11       Impact factor: 6.138

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.